2024年11月22日 · We demonstrate that SGN-CD47M is well tolerated in cynomolgus monkeys and displays a 20-fold improvement in tolerability to hematologic toxicities when compared with the unmasked antibody. SGN-CD47M also displays preferential activation in the TME that leads to robust single-agent antitumor activity.

2020年8月8日 · A CD47 antibody drug conjugate, SGN CD47M, has been developed by Seattle Genetics and is enrolling cancer patients for a phase 1 trial (NCT03957096), but no preclinical data have been published. Chitosan/hyaluronic acid polyelectrolyte complex nanoparticles were loaded with CD47 antibody and administered to atherosclerotic ApoE −/− mice fed ...

We demonstrate that SGN-CD47M is well tolerated in cynomolgus monkeys and displays a 20-fold improvement in tolerability to hematologic toxicities when compared to the unmasked antibody. SGN-CD47M also displays preferential activation in the tumor microenvironment that leads to robust single-agent antitumor activity.

2022年4月13日 · SGN-CD47M. SGN-CD47M, developed by Seagen (Seattle Genetics), is a CD47 targeting probody drug conjugate (PDCs). Probody therapeutics are antibody prodrugs designed to remain inactive until proteolytically cleaved and activated in the tumor microenvironment.

2021年9月18日 · 抗体偶联药物(ADC)领域，目前只有Seagen开发的CD47抗体偶联药物SGN-CD47M进入临床阶段，正在开展治疗晚期实体瘤的I期临床。 此外，Tallac的TAC-002是一款SIRPα抗体偶联TLR9激动剂，与ALX Oncology合作开发，还有Byondis开发的BYON4228.两款都 …

SGN-CD47M: 一种CD47抑制剂药物，由Seagen Inc. (Seagen Inc.)公司最早进行研发，目前全球最高研发状态为终止，作用机制: CD47抑制剂(分化群47抑制剂)，治疗领域: 肿瘤,消化系统疾病,内分泌与代谢疾病。

This is a dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of SGN-CD47M in adults with advanced solid tumors. The study will be conducted in 2 parts:

2019年5月17日 · 这是一项剂量递增研究，旨在评估 SGN-CD47M 在成人晚期实体瘤中的安全性、耐受性、药代动力学 (PK) 和抗肿瘤活性。 该研究将分两部分进行： A 部分——剂量递增：最多约 25 名患者将接受治疗，以评估 SGN-CD47M 的安全性、耐受性和 PK，并确定最大耐受剂量（MTD）和/或最佳剂量。 B 部分——剂量扩展：最多约 180 名患者将在 MTD 或最佳剂量的扩展队列中接受治疗，以进一步表征 SGN-CD47M 的安全性、PK 和抗肿瘤活性。 在符合条件的 …

2024年10月28日 · SGN-CD47M also displays preferential activation in the tumor microenvironment that leads to robust single-agent antitumor activity. For these reasons, SGN-CD47M may have enhanced antitumor ...

CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells. Sgn-cd47m has been investigated in 1 clinical trial, of which 0 are open and 1 is closed.